Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TOTUM-070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
TOTUM-070 is a combination of plant extracts that contains neither phytosterols nor red yeast rice, designed by VALBIOTIS’ proprietary R&D platform based in Riom (63).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TOTUM-070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020
Details:
VALBIOTIS expects to start a Phase II clinical trial evaluating the effect of TOTUM-070 in reducing LDL-cholesterol, in mild to moderate hypercholesterolemic patients.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
